Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly
used for the treatment of a wide variety of retinal diseases, including age-related macular …

Age-related macular degeneration is the leading cause of irreversible blindness in people
50 years of age or older in the developed world. This article reviews the clinical and …

Background: Age-related macular degeneration is a leading cause of severe, irreversible
vision impairment in developed countries. The primary risk factors for the development of …

Diabetes is a major cause of visual impairment among working-age adults in the United
States. The proliferative form of diabetic retinopathy is associated with severe vision loss …

Background Intraocular inflammation is an uncommon but potentially vision-threatening
adverse event related to anti-VEGF therapy. This is of increasing importance given both the …

Purpose: To report the rates of endophthalmitis and the spectrum of causative organisms
after intravitreal injection of anti-vascular endothelial growth factor agents and possible …

Previous research has implicated vascular endothelial growth factor (VEGF) in the
pathogenesis of diabetic retinopathy (DR). Although many studies reviewed the use of anti …

The treatment of ocular neovascular diseases is being revolutionized by intravitreal
therapies targeting vascular endothelial growth factor (VEGF). Two agents are approved for …

Lutein is one of the few xanthophyll carotenoids that is found in high concentration in the
macula of human retina. As de novo synthesis of lutein within the human body is impossible …

Intravitreal injections play a critical role in daily ophthalmic practice. The overall risk of
endophthalmitis and retinal detachment appears to be low and most of the commonly used …